Cardiology
Electrophysiology and Arrhythmia: Clinical Trial Design
Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide)Haanschoten D.M.a · Vernooy K.b · Beukema R.J.c · Szili-Torok T.d · ter Bekke R.M.A.b · Khan M.e · de Jong J.S.S.G.e · Otten A.M.f · Adiyaman A.a · Smit J.J.J.a · Delnoy P.P.H.M.a · Ramdat Misier A.R.a · Elvan A.aaIsala Heart Center, Zwolle, The Netherlands
bMaastricht UMC+, Maastricht, The Netherlands cRadboud UMC, Nijmegen, The Netherlands dErasmus UMC, Rotterdam, The Netherlands eOLVG, Amsterdam, The Netherlands fGelre Ziekenhuizen, Apeldoorn, The Netherlands |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 23, 2020
Accepted: June 23, 2020
Published online: August 25, 2020
Issue release date: December 2020
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Abstract
Background: Symptomatic idiopathic ventricular arrhythmias (VA), including premature beats (VPB) and nonsustained ventricular tachycardia (VT) are commonly encountered arrhythmias. Although these VA are usually benign, their treatment can be a challenge to primary and secondary health care providers. Mainstay treatment is comprised of antiarrhythmic drugs (AAD) and, in case of drug intolerance or failure, patients are referred for catheter ablation to tertiary health care centers. These patients require extensive medical attention and drug regimens usually have disappointing results. A direct comparison between the efficacy of the most potent AAD and primary catheter ablation in these patients is lacking. The ECTOPIA trial will evaluate the efficacy of 2 pharmacological strategies and 1 interventional approach to: suppress the VA burden, improve the quality of life (QoL), and safety. Hypothesis: We hypothesize that flecainide/verapamil combination and catheter ablation are both superior to sotalol in suppressing VA in patients with symptomatic idiopathic VA. Study Design: The Elimination of Ventricular Premature Beats with Catheter Ablation versus Optimal Antiarrhythmic Drug Treatment (ECTOPIA) trial is a randomized, multicenter, prospective clinical trial to compare the efficacy of catheter ablation versus optimal AAD treatment with sotalol or flecainide/verapamil. One hundred eighty patients with frequent symptomatic VA in the absence of structural heart disease or underlying cardiac ischemia who are eligible for catheter ablation with an identifiable monomorphic VA origin with a burden ≥5% on 24-h ambulatory rhythm monitoring will be included. Patients will be randomized in a 1:1:1 fashion. The primary endpoint is defined as >80% reduction of the VA burden on 24-h ambulatory Holter monitoring. After reaching the primary endpoint, patients randomized to one of the 2 AAD arms will undergo a cross-over to the other AAD treatment arm to explore differences in drug efficacy and QoL in individual patients. Due to the use of different AAD (with and without β-blocking characteristics) we will be able to explore the influence of alterations in sympathetic tone on VA burden reduction in different subgroups. Finally, this study will assess the safety of treatment with 2 different AAD and ablation of VA.
© 2020 S. Karger AG, Basel
Related Articles:
References
- Adams JC, Srivathsan K, Shen WK. Advances in management of premature ventricular contractions. J Interv Card Electrophysiol. 2012 Nov;35(2):137–49.
- Kostis JB, McCrone K, Moreyra AE, Gotzoyannis S, Aglitz NM, Natarajan N, et al. Premature ventricular complexes in the absence of identifiable heart disease. Circulation. 1981 Jun;63(6):1351–6.
- Huizar JF, Kaszala K, Potfay J, Minisi AJ, Lesnefsky EJ, Abbate A, et al. Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for PVC-induced cardiomyopathy. Circ Arrhythm Electrophysiol. 2011 Aug;4(4):543–9.
-
Roca-Luque I, Mont L. Frequent premature ventricular complexes and normal ejection fraction: to treat or not to treat? Vol. 105, Heart. BMJ Publishing Group; 2019. pp. 1386–7.
- Lee AK, Andrade J, Hawkins NM, Alexander G, Bennett MT, Chakrabarti S, et al. Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart. 2019 Sep;105(18):1408–13.
- Stec S, Sikorska A, Zaborska B, Kryński T, Szymot J, Kułakowski P. Benign symptomatic premature ventricular complexes: short- and long-term efficacy of antiarrhythmic drugs and radiofrequency ablation. Kardiol Pol. 2012;70(4):351–8.
- Ling Z, Liu Z, Su L, Zipunnikov V, Wu J, Du H, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014 Apr;7(2):237–43.
- Dogan M, Yiginer O, Uz O, Kucuk U, Degirmencioglu G, Isilak Z, et al. The effects of female sex hormones on ventricular premature beats and repolarization parameters in physiological menstrual cycle. Pacing Clin Electrophysiol. 2016 May;39(5):418–26.
- Saba S, Zhu W, Aronovitz MJ, Estes NA 3rd, Wang PJ, Mendelsohn ME, et al. Effects of estrogen on cardiac electrophysiology in female mice. J Cardiovasc Electrophysiol. 2002 Mar;13(3):276–80.
- Namtvedt SK, Randby A, Einvik G, Hrubos-Strøm H, Somers VK, Røsjø H, et al. Cardiac arrhythmias in obstructive sleep apnea (from the Akershus Sleep Apnea Project). Am J Cardiol. 2011 Oct;108(8):1141–6.
- Haemers P, Sutherland G, Cikes M, Jakus N, Holemans P, Sipido KR, et al. Further insights into blood pressure induced premature beats: transient depolarizations are associated with fast myocardial deformation upon pressure decline. Heart Rhythm. 2015 Nov;12(11):2305–15.
- Hamon D, Abehsira G, Gu K, Liu A, Blaye-Felice Sadron M, Billet S, et al. Circadian variability patterns predict and guide premature ventricular contraction ablation procedural inducibility and outcomes. Heart Rhythm. 2018 Jan;15(1):99–106.
- Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace. 2014 Sep;16(9):1257–83.
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep;138(13):e210–71.
- Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed By: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov;36(41):2793–867.
-
Efficacy and safety of flecainide in patients with stable ventricular ectopic beats: multicenter trial of the Italian Study Group on the Electrophysiology of Arrhyhtmias. G Ital Cardiol. 1989 Apr;19(4):360–70.
- Saikawa T, Niwa H, Ito M, Ishida S, Nakagawa M, Maeda T, et al. The effect of propafenone on premature ventricular contractions (PVC): an analysis based on heart rate dependency of PVCs. Jpn Heart J. 2001 Nov;42(6):701–11.
- Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007 Jul;4(7):863–7.
- Zhong L, Lee YH, Huang XM, Asirvatham SJ, Shen WK, Friedman PA, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm. 2014 Feb;11(2):187–93.
- Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR, et al. Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful? Am Heart J. 2013 Aug;166(2):381–7.e8.
- Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016 Jun;19(4):343–52.
- Gao X, Guha A, Buck B, Patel D, Snider MJ, Boyd M, et al. Initiation and outcomes with Class Ic antiarrhythmic drug therapy. Indian Pacing Electrophysiol J. 2018 Mar-Apr;18(2):68–72.
Article / Publication Details
Received: April 23, 2020
Accepted: June 23, 2020
Published online: August 25, 2020
Issue release date: December 2020
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
